Benitec Biopharma (NASDAQ:BNTC) is a dynamic biotechnology firm focused on the development of genetic medicines. Benitec's innovative approach leverages its proprietary gene-silencing technology, called DNA-directed RNA interference (ddRNAi), to create therapies aimed at treating chronic and life-threatening diseases. The company's pipeline includes projects targeting conditions such as hepatitis B, age-related macular degeneration, and oculopharyngeal muscular dystrophy, showcasing its commitment to addressing unmet medical needs through groundbreaking research. With a mission to pioneer the next generation of genetic medicines, Benitec strives to improve patient outcomes and alter the course of disease with its cutting-edge technologies and therapies.